

**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING
Capitol Annex -Room 131**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, September 21, 2017
1:00 P.M. to 4:30 P.M.

AGENDA

- I. Call to Order and Welcome**
- II. Old Business**
 - a. Approval of Minutes: March 16, 2017 and May 18, 2017 Meeting
- III. New Business**
 - a. New Products to Market
 - i. Arymo™ ER
 - ii. MorphaBond™ ER
 - iii. Xadago®
 - iv. Tymlos™
 - v. Kevzara®
 - vi. Siliq™
 - vii. Trulance™
 - viii. AirDuo™ RespiClick®
 - ix. Emflaza™
 - x. Dupixent®
 - xi. Kisqali®
 - xii. Rydapt®
 - xiii. Alunbrig™
 - xiv. Zejula™

Note: New product Rhofade™ to be discussed within the class review – Rosacea Agents, Topical.

- IV. Criteria Review**
 - a. Yosprala™ Criteria Review
 - b. Anxiolytics Criteria Review
 - c. Sedative Hypnotics Criteria Review
- V. Therapeutic Classes with Recommended Changes**
 - a. Angiotensin Modulators
 - i. Angiotensin Converting Enzyme Inhibitors (ACEi)
 - ii. ACEi + Diuretic
 - iii. Angiotensin Receptor Blocker (ARB)
 - iv. ARB + Diuretic
 - v. Direct Renin Inhibitors
 - b. Antifungals, Topical
 - c. Beta-Blockers

- d. Leukotriene Modifiers
 - i. Criteria Review
- e. Lipotropics, Statins
- f. Rosacea Agents, Topical – includes new product; Rhofade™

VI. Consent Agenda

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Alzheimer’s Agents	Bladder Relaxant Preparations
Androgenic Agents	Erythropoiesis Stimulating Proteins
Angiotensin Modulator Combinations	Nasal Preparations – Antibiotics
Anticonvulsants	Otic Antibiotics
Antidepressants, SSRIs	Otics, Anti-Inflammatories
Antihistamines, Minimally Sedating	PAH Agents – Oral and Inhaled
Antihyperuricemics	Phosphate Binders
Antiparasitics, Topical	Ulcerative Colitis Agents
Antipsoriatics, Oral	Vasodilators, Coronary
Antivirals, Topical	

- b. The following therapeutic classes have no recommended changes other than a brand/generic switch. These may be voted on as a group:

Antidepressants, Other

- c. The following therapeutic classes have no recommended changes other than specific formulation movement. These may be voted on as a group:

N/A

VII. Executive Session

VIII. Adjournment

- a. Next Meeting
 - i. **November 16, 2017**
- b. Collection of Travel Vouchers

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.